Current and Emerging Treatments for Myelodysplastic Syndromes: The 2021 Landscape

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: October 25, 2021
Expiration Date: October 25, 2022

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Historically, there have been few effective treatment options for MDS, creating a critical unmet need for therapies. New agents approved in 2020 represent the first new options for MDS in the last several years. Additional novel agents are on the horizon which hold promise to impact the current treatment paradigm.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify MDS subtypes that correlate specific molecular mutations with targeted treatment plans
  • Utilize a conceptual framework for risk-adapted therapy for low- and high-risk MDS to select optimal treatment approaches
  • Discuss options for relapsed/refractory lower-risk MDS and investigational new agents in lower-risk MDS with patients and families

Agenda

Genetics, Risk Stratification, and Managing Lower-risk MDS – Mikkael A. Sekeres, MD, MS

Choosing Optimal Therapeutic Strategies in Higher-risk MDS – Amy E. DeZern, MD, MHS

Instructions for Participation and Credit

This activity is eligible for credit through October 25, 2022. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Mikkael A. Sekeres, MD, MS
Professor of Medicine
Chief of the Division of Hematology
Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine
Miami, Florida

Dr. Mikkael Sekeres earned a medical degree and a master’s degree in clinical epidemiology from the University of Pennsylvania School of Medicine. He completed his postgraduate training at Harvard University, finishing an internal medicine residency at Massachusetts General Hospital, and a fellowship in hematology-oncology at the Dana-Farber Cancer Institute in Boston. Dr. Sekeres is Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine.

Dr. Sekeres is chair of the medical advisory board of the Aplastic Anemia and Myelodysplastic Syndrome (MDS) International Foundation. An invited speaker at numerous meetings, grand rounds, and conferences, Dr. Sekeres is a member of the American Society of Hematology, where he is also on the executive committee, the American Society of Clinical Oncology, and the Southwest Oncology Group—Leukemia Committee. His research focuses on patients with MDS and older adults with acute myeloid leukemia, and he has been the national and international primary study investigator on several phase I/II/III trials. Dr. Sekeres is the author/co-author of more than 350 manuscripts and 650 abstracts published in The New England Journal of Medicine, Blood, Journal of Clinical Oncology, Nature Genetics, Cancer Cell, Journal of the National Cancer Institute, Journal of Clinical Investigation, PLoS One, and Leukemia. He is on the editorial board of several journals, has written more than 50 essays for The New York Times, and has authored seven books, including When Blood Breaks Down: Life Lessons from Leukemia.

Amy E. DeZern, MD, MHS
Associate Professor of Oncology and Medicine
Department of Oncology
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins School of Medicine
Baltimore, Maryland

Dr. Amy DeZern received her medical degree from The Johns Hopkins University School of Medicine. She completed an internship and residency, as well as a fellowship in medical oncology and hematology at Johns Hopkins University School of Medicine. Dr. DeZern received her masters of health science in clinical investigation at Johns Hopkins Bloomberg School of Public Health, followed by a fellowship at Sidney Kimmel Comprehensive Cancer Center (SKCCC). She is an Associate Professor of Oncology and Medicine in the Department of Oncology at SKCCC at Johns Hopkins University School of Medicine, and is an Attending Physician at The Johns Hopkins Hospital in Baltimore.

Dr. DeZern is a clinical investigator with a focus on translation of novel treatments to the clinic, her goal is to improve outcomes for patients with bone marrow failure in a research environment. Her principal research activities consist of designing and conducting clinical trials that test investigational therapies and approaches in the treatment of bone marrow failure (aplastic anemia and myelodysplastic syndromes). She has specific expertise in the use of alternative donor bone marrow transplantation in patients with severe aplastic anemia and trials of novel therapeutics for patients with myelodysplastic syndromes, and she has taken a rigorous approach to the study of transfusion therapies in these patient populations. In addition, Dr. DeZern has been the Principal Investigator for a number of multicenter trials in collaboration with the MDS Clinical Research Consortium, the Eastern Co-operative Oncology Group (ECOG)-ACRIN, and the Bone Marrow Trials Clinical Trials Network (BMTCTN), and is study chair for the phase II BMTCTN study (CHAMP) investigating the role of haploidentical donor transplantation using post-transplantation cyclophosphamide in patients with relapsed several aplastic anemia. Dr. DeZern is also the local PI as well as deputy co-chair for The National MDS Study, a collaborative natural history study of the NHLBI and the NCI.

Accreditation

MediCom CME CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-21-041-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.

MediCom NURSING CREDIT
MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 21-041-151
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Disclosures

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosures

Dr. Mikkael Sekeres has relevant financial relationships related to advisory activities from Bristol-Myers Squibb Company, Novartis AG, and Takeda Oncology.

Dr. Amy DeZern has relevant financial relationships related to advisory activities from AbbVie Inc., Bristol-Myers Squibb Company, and Novartis AG, as well as relevant financial relationships related to the development of educational materials from Taiho Pharmaceutical Co., Ltd.

All of the relevant financial relationships listed for these individuals have been mitigated.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee

Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at cmettille@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Astex Pharmaceuticals, Inc.

©2021 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.